세계의 POC(현장 진단) 지질 검사 시장 : 산업규모, 점유율, 동향, 기회, 예측, 제품별, 용도별, 적응 질환별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Point of Care Lipid Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Disease Indication, By End User, By Region and Competition, 2020-2030F
세계의 POC 지질 검사 시장은 2024년에는 7억 3,561만 달러로 평가되었고, 2030년까지는 10억 7,248만 달러에 이를 것으로 예측되며, CAGR은 6.46%를 나타낼 전망입니다.
이 시장은 심혈관 질환의 발생률 증가와 조기 지질 수치 검사의 중요성 강화에 힘입어 안정적으로 성장하고 있습니다. POC(현장 진단) 지질 검사는 신속하고 정확한 진단을 제공하여 일차 진료 및 응급 상황에서 임상적 결정을 지원합니다. 건강 인식 향상과 예방 의료에 대한 강조는 POC 지질 검사의 채택을 가속화했으며, 의사 및 환자 모두에게 사용 편의성과 진단 가치로 인해 인기를 얻고 있습니다. 모바일 클리닉과 지역 약국에의 통합은 접근성을 더욱 향상시키고 있습니다. 블루투스와 클라우드 기능을 갖춘 휴대용 지질 분석기의 기술 발전은 환자 모니터링과 전자 건강 기록과의 데이터 통합을 혁신하고 있습니다. 다중 바이오마커를 동시에 검사할 수 있는 다중 분석 플랫폼에 대한 수요가 증가하고 있으며, 이는 분산형 진단과 가치 기반 의료 서비스 제공으로의 전환을 보완하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모(2024년) |
7억 3,561만 달러 |
| 시장 규모(2030년) |
10억 7,248만 달러 |
| CAGR(2025-2030년) |
6.46% |
| 급성장 부문 |
동맥경화증 |
| 최대 시장 |
북미 |
주요 시장 성장 촉진요인
심혈관 질환 및 이상지질혈증의 증가
주요 시장 과제
정확성과 신뢰성에 대한 우려
주요 시장 동향
디지털 의료 기술 통합
목차
제1장 제품 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 제품별(기기, 소모품)
- 용도별(고지혈증, 고트리글리세리드혈증, 탄질병, 고리포단백혈증, 가족성 고콜레스테롤혈증, 기타)
- 적응 질환별(지질 및 리포단백질 질환, 동맥경화증, 간 질환 및 신 질환, 당뇨병, 기타)
- 최종 사용자별(병원, 진료소, 연구 및 진단 실험실, 기타)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 POC 지질 검사 시장 전망
- 시장 규모와 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향 및 발전
제13장 혼란 : 분쟁, 유행, 무역 장벽
제14장 Porter's Five Forces 분석
- 업계 내 경쟁
- 신규 진입의 가능성
- 공급자의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Callegari Srl
- Sinocare Inc.
- Abbott Laboratories
- MiCoBio
- Nova Biomedical
- VivaChek Biotech(Hangzhou) Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Menarini Group
- SD Biosensor, Inc.
- Becton, Dickinson and Company
제16장 전략적 제안
제17장 기업 소개 및 면책사항
HBR
The Global Point of Care Lipid Test Market was valued at USD 735.61 Million in 2024 and is projected to reach USD 1072.48 Million by 2030, registering a CAGR of 6.46%. The market is expanding steadily, driven by the rising incidence of cardiovascular diseases and the growing importance of early lipid level detection. Point-of-care (POC) lipid testing offers rapid, accurate diagnostics, supporting timely clinical decisions in primary care and emergency settings. Increasing health awareness and emphasis on preventive care have accelerated the adoption of POC lipid tests, which are gaining popularity among both physicians and patients for their ease of use and diagnostic value. Their integration into mobile clinics and community pharmacies further enhances accessibility. Advancements in portable lipid analyzers with Bluetooth and cloud capabilities are also transforming patient monitoring and data integration with electronic health records. The demand for multi-analyte platforms that test for multiple biomarkers simultaneously is on the rise, complementing the shift toward decentralized diagnostics and value-based healthcare delivery.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 735.61 Million |
| Market Size 2030 | USD 1072.48 Million |
| CAGR 2025-2030 | 6.46% |
| Fastest Growing Segment | Atherosclerosis |
| Largest Market | North America |
Key Market Drivers
Rising Prevalence of Cardiovascular Diseases and Dyslipidemia
The increasing global burden of cardiovascular diseases (CVDs) and dyslipidemia is a primary driver of the Point of Care (POC) Lipid Test Market. Conditions such as coronary artery disease, hypertension, and stroke remain among the leading causes of death. Dyslipidemia, defined by abnormal cholesterol or triglyceride levels, is a major risk factor. In 2020, nearly 12% of U.S. adults had high total cholesterol, with over 38% displaying borderline or elevated levels. POC lipid testing allows for immediate results, enabling prompt therapeutic actions like prescribing statins or initiating lifestyle interventions. These tests are especially beneficial in primary care, outpatient clinics, and community screenings, helping improve patient compliance and supporting proactive cardiovascular risk management. Public health campaigns have also incorporated POC lipid testing, particularly in rural and underserved areas.
Key Market Challenges
Concerns Regarding Accuracy and Reliability
A notable challenge for the POC lipid test market is the ongoing concern over test accuracy and reliability compared to laboratory-based diagnostics. While the convenience and speed of POC tests are appealing, variability in calibration, operator handling, and environmental conditions can compromise test performance. These inconsistencies may lead to incorrect readings, influencing clinical decisions and potentially affecting patient safety. The diagnostic accuracy of some devices remains under scrutiny, particularly in uncontrolled environments, creating hesitation among clinicians and regulatory bodies. The lack of standardized manufacturing practices and rigorous quality validation also impacts market confidence. In lower-resource settings, insufficient training and infrastructure further limit the reliability of test outcomes. Addressing these concerns will require standardized quality benchmarks, broader training programs, and enhanced device design to match lab-grade diagnostic standards.
Key Market Trends
Integration of Digital Health Technologies
The market is undergoing a digital transformation as point-of-care lipid testing devices increasingly integrate with digital health technologies. These devices now feature real-time data transfer capabilities to electronic health records (EHRs), enhancing clinical decision-making and workflow efficiency. Cloud-based systems support centralized data storage, remote access, and predictive analytics, enabling proactive risk management. Smartphone-compatible devices and mobile health applications allow patients to track cholesterol levels, medication adherence, and lifestyle habits from home, fostering a more engaged and personalized approach to lipid management. Artificial intelligence (AI) and machine learning (ML) tools are also being introduced to interpret test data more accurately and identify complex risk patterns. These innovations align with value-based care strategies and are particularly valuable in supporting long-term disease prevention and management.
Key Market Players
- Callegari Srl
- Sinocare Inc.
- Abbott Laboratories
- MiCoBio
- Nova Biomedical
- VivaChek Biotech (Hangzhou) Co., Ltd.
- F. Hoffmann-La Roche Ltd.
- Menarini Group
- SD Biosensor, Inc.
- Becton, Dickinson and Company
Report Scope
In this report, the Global Point of Care Lipid Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Point of Care Lipid Test Market, By Product:
Point of Care Lipid Test Market, By Application:
- Hyperlipidemia
- Hypertriglyceridemia
- Tangier Disease
- Hyperlipoproteinemia
- Familial Hypercholesterolemia
- Others
Point of Care Lipid Test Market, By Disease Indication:
- Lipid and Lipoprotein Disorders
- Atherosclerosis
- Liver and Renal Diseases
- Diabetes Mellitus
- Others
Point of Care Lipid Test Market, By End User:
- Hospitals
- Clinics
- Research and Diagnostic Laboratories
- Others
Point of Care Lipid Test Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Lipid Test Market.
Available Customizations
Global Point of Care Lipid Test Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Point of Care Lipid Test Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Instruments, Consumables)
- 5.2.2. By Application (Hyperlipidemia, Hypertriglyceridemia, Tangier Disease, Hyperlipoproteinemia, Familial Hypercholesterolemia, Others)
- 5.2.3. By Disease Indication (Lipid and Lipoprotein Disorders, Atherosclerosis, Liver and Renal Diseases, Diabetes Mellitus, Others)
- 5.2.4. By End User (Hospitals, Clinics, Research and Diagnostic Laboratories, Others)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
- 5.3. Market Map
6. North America Point of Care Lipid Test Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Application
- 6.2.3. By Disease Indication
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Point of Care Lipid Test Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Application
- 6.3.1.2.3. By Disease Indication
- 6.3.1.2.4. By End User
- 6.3.2. Mexico Point of Care Lipid Test Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Application
- 6.3.2.2.3. By Disease Indication
- 6.3.2.2.4. By End User
- 6.3.3. Canada Point of Care Lipid Test Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Application
- 6.3.3.2.3. By Disease Indication
- 6.3.3.2.4. By End User
7. Europe Point of Care Lipid Test Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Disease Indication
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Point of Care Lipid Test Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Disease Indication
- 7.3.1.2.4. By End User
- 7.3.2. Germany Point of Care Lipid Test Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Disease Indication
- 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Point of Care Lipid Test Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Disease Indication
- 7.3.3.2.4. By End User
- 7.3.4. Italy Point of Care Lipid Test Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Application
- 7.3.4.2.3. By Disease Indication
- 7.3.4.2.4. By End User
- 7.3.5. Spain Point of Care Lipid Test Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Application
- 7.3.5.2.3. By Disease Indication
- 7.3.5.2.4. By End User
8. Asia-Pacific Point of Care Lipid Test Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Disease Indication
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Point of Care Lipid Test Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Disease Indication
- 8.3.1.2.4. By End User
- 8.3.2. India Point of Care Lipid Test Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Disease Indication
- 8.3.2.2.4. By End User
- 8.3.3. South Korea Point of Care Lipid Test Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Disease Indication
- 8.3.3.2.4. By End User
- 8.3.4. Japan Point of Care Lipid Test Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Disease Indication
- 8.3.4.2.4. By End User
- 8.3.5. Australia Point of Care Lipid Test Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Disease Indication
- 8.3.5.2.4. By End User
9. South America Point of Care Lipid Test Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Disease Indication
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Point of Care Lipid Test Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Disease Indication
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Point of Care Lipid Test Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Disease Indication
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Point of Care Lipid Test Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Disease Indication
- 9.3.3.2.4. By End User
10. Middle East and Africa Point of Care Lipid Test Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Disease Indication
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Point of Care Lipid Test Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Disease Indication
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Point of Care Lipid Test Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Disease Indication
- 10.3.2.2.4. By End User
- 10.3.3. UAE Point of Care Lipid Test Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Disease Indication
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Merger & Acquisition (If Any)
- 12.2. Product Launches (If Any)
- 12.3. Recent Developments
13. Disruptions: Conflicts, Pandemics and Trade Barriers
14. Porters Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products
15. Competitive Landscape
- 15.1. Callegari Srl
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. Sinocare Inc.
- 15.3. Abbott Laboratories
- 15.4. MiCoBio
- 15.5. Nova Biomedical
- 15.6. VivaChek Biotech (Hangzhou) Co., Ltd.
- 15.7. F. Hoffmann-La Roche Ltd.
- 15.8. Menarini Group
- 15.9. SD Biosensor, Inc.
- 15.10. Becton, Dickinson and Company
16. Strategic Recommendations
17. About Us & Disclaimer
